Collectively, our study highlights the strong need for effective, selective, and safe androgen receptor blockers to mitigate not only metabolic and cardiovascular symptoms in women with PCOS but also possible COVID-19-associated outcomes. This evidence concerns the gene AR and polycystic ovary syndrome.